Eicosapentaenoic acid (all cis-5,8,11,14,17)Eicosapentaenoic acid (all cis-5,8,11,14,17)
Move your mouse over image or click to enlarge

Eicosapentaenoic acid (all cis-5,8,11,14,17)

EPA; omega-3 Fatty acid; C20:5 (all cis-5,8,11,14,17) Fatty acid [Anti-hyperlipoproteinenic agent; 5-LOX inhibitor]

Eicosapentaenoic acid (EPA) is an omega-3 fatty acid and is an essential fatty acid in mammals. It is among the most abundant polyunsaturated fatty acids in fish oil although fish obtain EPA from algae. Levels of EPA (and other omega-3 fatty acids) have been linked to many diseases and disorders. Low levels of EPA are associated with depression, schizophrenia, and Alzheimer’s disease1 and supplementation with EPA is being investigated for its use as a treatment. However, a diet rich in EPA may lead to enhanced lipid peroxidation. It is anti-hyperlipoproteinic (helps prevent abnormal lipid levels in the blood) and it is thought to help reduce the risk of atherosclerosis, sudden cardiac death, neurodegeneration, and various inflammatory disorders. EPA is also thought to be able to increase the beneficial effects of chemotherapy and may help to prevent cancer and attenuate responses of T-cells and macrophages. EPA also improves insulin sensitivity while at the same time inhibiting cell proliferation2 and has been found to activate epithelial sodium channels. Recent studies suggest that oxidized (as opposed to native) EPA is responsible for anti-atherosclerotic, anti-inflammatory, and anti-proliferative effects.3
Cat# Size Price Qty Buy
1167 25 mg £126.56

Additional Information

Property Value or Rating
Product Size 25 mg
Manufacturer Matreya, LLC
Empirical Formula C20H30O2
CAS# 10417-94-4
Formula Weight 302
Solvent none
Source natural
Purity 99%
Analytical Methods GC, TLC
Natural Source fish oil
Solubility chloroform, hexane, ethyl ether, ethanol, DMSO, DMF
Physical Appearance liquid
Storage -20°C
Dry Ice No
Hazardous Yes
References

1. C. Song, S. Zhao “Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations.” Expert Opin Investig Drugs, Vol. 16(10) pp. 1627-1638, 2007 
2. Masahiro Murata “Dual Action of Eicosapentaenoic Acid in Hepatoma Cells UP-REGULATION OF METABOLIC ACTION OF INSULIN AND INHIBITION OF CELL PROLIFERATION” Journal of Biological Chemistry, Vol. 276 pp. 31422-31428, 2001 
3. Jason D. Morrow “Formation of Highly Reactive Cyclopentenone Isoprostane Compounds (A3/J3-Isoprostanes) in Vivo from Eicosapentaenoic Acid” Journal of Biological Chemistry, Vol. 283 pp. 12043-12055, 2008

Related Documents